Literature DB >> 32686081

Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia.

Marco Cerrano1,2, Barbara Castella3, Giuseppe Lia2, Matteo Olivi1,2, Danilo G Faraci1,2, Sara Butera1,2, Federica Martella1,2, Matilde Scaldaferri4, Francesco Cattel4, Mario Boccadoro1,2, Massimo Massaia5, Dario Ferrero1,2, Benedetto Bruno1,2, Luisa Giaccone1,2.   

Abstract

Entities:  

Keywords:  T acute lymphoblastic leukaemia; acute leukaemia; daratumumab; immunomodulation; immunotherapy

Mesh：

Substances：

Year:  2020        PMID： 32686081     DOI： 10.1111/bjh.16960

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?

Authors:  Nicola Gökbuget
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.

Authors:  Marco Cerrano; Massimiliano Bonifacio; Matteo Olivi; Antonio Curti; Michele Malagola; Michelina Dargenio; Anna Maria Scattolin; Cristina Papayannidis; Fabio Forghieri; Carmela Gurrieri; Ilaria Tanasi; Patrizia Zappasodi; Roberta La Starza; Nicola Stefano Fracchiolla; Patrizia Chiusolo; Luisa Giaccone; Maria Ilaria Del Principe; Fabio Giglio; Marzia Defina; Claudio Favre; Carmelo Rizzari; Barbara Castella; Giovanni Pizzolo; Felicetto Ferrara; Sabina Chiaretti; Robin Foà
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

3.  Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript.

Authors:  Sophie Voruz; Sabine Blum; Laurence de Leval; Jacqueline Schoumans; Françoise Solly; Olivier Spertini
Journal:  Biomark Res       Date:  2021-12-20

Review 4.  A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies.

Authors:  Haley Newman; David T Teachey
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.